Company Profile

SANOFI INDIA LTD.

NSE : SANOFIBSE : 500674ISIN CODE : INE058A01010Industry : Pharmaceuticals & DrugsHouse : Sanofi India - MNC
BSE8275.85-91.8 (-1.1 % )
PREV CLOSE (Rs.) 8367.65
OPEN PRICE (Rs.) 8375.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1013
TODAY'S LOW / HIGH (Rs.)8118.10 8398.00
52 WK LOW / HIGH (Rs.)7427.75 9300
NSE8271.15 -105.8 (-1.26 % )
PREV CLOSE(Rs.) 8376.95
OPEN PRICE (Rs.) 8394.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 8271.15 (2 )
VOLUME 12966
TODAY'S LOW / HIGH(Rs.) 8114.00 8408.15
52 WK LOW / HIGH (Rs.)7056.55 9285

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 4.41
TTM EPS (Rs.) 251.88
P/E Ratio 32.86
Book Value (Rs.) 697.04
Face Value (Rs.) 10
MCap (Rs. in Mn) 190597.97
Price/Earning (TTM) 28.77
Price/Sales (TTM) 6.52
Price/Book (MRQ) 11.87
PAT Margin (%) 15.64
ROCE (%) 29.77
Incorporation Year : 1956

Management Info :

Aditya Narayan - Chairman Rajaram Narayanan - Managing Director

Registered Office :

Address : Sanofi House, 117-b,L&t Business Park,Saki Vihar Road, Powai,
Mumbai,
Maharashtra-400072

Phone :

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
13Oct10-13-2021$ Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2021 (Q3). Board Meeting Intimation fo
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, 26th October 2021; inter alia to consider the unaudited financial results for the quarter and nine months ended 30th September 2021 (Q3).
Sanofi India Ltdhas informed BSE that the meeting of the Board..
06Oct10-06-2021$Sanofi India informs about details of loss of share certificate Sanofi India informs about d

Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Sanofi India has informed that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and..
30Sep09-30-2021$ Closing Of Transaction Relating Slump Sale And Transfer Of The Nutraceuticals Business Of The Company Closing Of Transaction Rela
Please find enclosed announcement related to closing of transaction relating Slump Sale and transfer of the Nutraceuticals business of the Company for your information and records.
Please find enclosed announcement related to closing of transac..
15Sep09-15-2021$Sanofi India informs about details of loss of share certificate Sanofi India informs about d

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Sanofi India has informed that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s) from shareholder Vinod Jetly: Ashu Jetly, details of which are enclosed.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and D..
24Aug08-24-2021$Sanofi India informs about disclosures of related party transactions Sanofi India informs about d

Sanofi India has informed that the unaudited financial results of the Company for the quarter and half year ended 30th June 2021 were approved by the Board of Directors of the Company at its meeting held on 27th July 2021 and published on 29th July 2021. Pursuant to Regulation 23(9) of Listing Regulations, the company has enclosed the disclosures of related party transactions for the half year ended 30th June 2021 in the format specified in the applicable accounting standards.

The above information is a part of company’s filings submitted to BSE.

Sanofi India has informed that the unaudited financial results..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 20
Net Profit17834776
Gross Profit 2426 6772
Operating Profit 26428029
Net Sales 789129019
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Torrent Pharma (BSE)
 3084.55 (3.91%)
M.Cap ( in Cr)
52193.28
NGL Fine-Chem (BSE)
 2554.25 (4.38%)
M.Cap ( in Cr)
1578.02
Venus Remedies (BSE)
 502.90 (14.73%)
M.Cap ( in Cr)
672.23
Kwality Pharma (BSE)
 913.50 (5.00%)
M.Cap ( in Cr)
947.87
Dr. Reddy's Lab (BSE)
 4675.45 (0.85%)
M.Cap ( in Cr)
77798.93
Shareholding Pattern More
FI/BANKS/INSURANCE 7.21 %
PROMOTERS 60.4 %
NON-INSTITUTION 11.59 %
MUTUAL FUNDS/UTI 10.44 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes